Icatibant Auxilia (Icatibant Acetate)

Icatibant is a selective competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑mediated vasodilation and increased vascular permeability, which are the primary mechanisms that cause the swelling seen in hereditary angioedema attacks.

The dose of icatibant is determined by the prescribing healthcare professional based on the patient’s clinical condition and regulatory guidelines. The prescriber will decide the appropriate amount and frequency for each individual case.

The safety of icatibant in pregnancy and while breastfeeding has not been established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other approved HAE therapies include C1‑inhibitor concentrates and kallikrein inhibitors. Icatibant works by directly blocking bradykinin effects, offering a rapid subcutaneous option, while C1‑inhibitor products replace the deficient protein and are administered intravenously.

Icatibant should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temporary temperature excursions occur, follow the manufacturer’s guidance before use.

Icatibant is supplied as a sterile injection solution for subcutaneous use. The medication is injected into the subcutaneous tissue, typically in the abdomen or thigh, by a trained healthcare professional or a patient who has been instructed on proper technique.

The most serious risks include severe allergic reactions such as anaphylaxis, marked hypotension, and systemic angioedema affecting areas other than the treated site. Patients should be monitored for these rare but potentially life‑threatening events and seek immediate medical attention if they occur.

Icatibant should not be used by individuals with a known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients taking ACE inhibitors or ARBs, and those with uncontrolled cardiovascular conditions should be evaluated before use.